Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Generic Use Rate at 77.1% in October-December 2019: JGA
March 27, 2020
- Japan Pharma Lobbies Hammer Out One-Year Term Extensions for Their Leaders
March 24, 2020
- JPMA Chief Fires Back at Health Policy Advisor’s “Plenty of Financial Strength” Comment
March 23, 2020
- JPMA Members Increasing Drug Stockpiles to Deal with COVID-19, Need Govt Support: Chief
March 23, 2020
- Japanese Drug Firms Providing APIs for NIID Screening for COVID-19: JPMA Survey
March 19, 2020
- Teshirogi, Nakayama to Lead Japan Pharma Lobbies for 1 More Year; Ex-MHLW Official Shiraishi to Join JPMA
March 16, 2020
- India’s API Export Curb Could Eventually Affect At Least 2 Firms, FPMAJ Finds
March 10, 2020
- Japan Infectious Diseases Society Shares Latest Knowledge on Antivirals against COVID-19
February 28, 2020
- Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
- PhRMA Japan Continues Push Against Off-Year Re-Pricing for Innovative Drugs, HTA Use in Reimbursement Decisions in 2020
February 20, 2020
- FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
- Drug Formularies Won’t Invade Doctors’ Rights to Prescribe: Payer Rep
February 10, 2020
- RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games
February 6, 2020
- Insurance Association to Send Copayment Differences Notification to 15 Year-Old and Over as well to Achieve 80% Generic Target
February 6, 2020
- Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped
February 5, 2020
- JPMA, Tohoku Medical Megabank to Start Collaborative Research on Preemptive Health
January 30, 2020
- JPMA Wants Revamped System for New Drug Evaluation, Improved Process in 2022 Reform
January 29, 2020
- Generic Industry Will Need Strategies Beyond Core Business for “Post-80%” Era: JGA President
January 23, 2020
- Revoke Conditional OK for Stemirac: Drug Damage Watchdog
January 23, 2020
- Japanese Pharma CEOs Gearing Up for New Endeavors in 2020, Fret Scope of Off-Year Re-Pricing
January 9, 2020
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…